Analyst Ratings For CLVS – Clovis Oncology (NASDAQ:CLVS)
Today, Bank of America reiterated its Buy rating on CLVS – Clovis Oncology (NASDAQ:CLVS) with a price target of $55.52.
Some recent analyst ratings include
- 4/9/2018-Bank of America Reiterated Rating of Buy.
- 4/8/2018-Cann Reiterated Rating of Hold.
- 2/22/2018-Evercore ISI Upgrade from a “In-Line ” rating to a ” Outperform” rating.
- On 3/8/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $61.47 per share and the total transaction amounting to $276,615.00.
- On 2/22/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $60.00 per share and the total transaction amounting to $270,000.00.
- On 2/15/2018 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $54.09 per share and the total transaction amounting to $162,270.00.
- On 1/16/2018 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $59.16 per share and the total transaction amounting to $177,480.00.
- On 1/8/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $64.97 per share and the total transaction amounting to $292,365.00.
- On 12/15/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $64.16 per share and the total transaction amounting to $192,480.00.
- On 12/8/2017 Thorlef Spickschen, Director, sold 4,500 with an average share price of $60.00 per share and the total transaction amounting to $270,000.00.
Recent Trading Activity for CLVS – Clovis Oncology (NASDAQ:CLVS)
Shares of CLVS – Clovis Oncology closed the previous trading session at 57.92 up +2.40 4.32% with 56.55009841918945 shares trading hands.